Tampere, Finland-based Bioretec Ltd., a medical device company focused on orthopedic implants, has appointed Rami Ojala as sales and marketing director and member of its management team, beginning on January 1, 2022.
Bioretec Names New Sales and Marketing Director
1 min read Premium comments
Secondary#bioretec#ramiojala
Ojala will succeed Lauri Hokkanen who will be leaving Bioretec for “new career opportunities outside the company.” Hokkanen will remain with Bioretec through January 31, 2022, to help transition Ojala to his new role.
Ojala has nearly 15 years of medical device sales and marketing experience. Since 2017, he has served as Impulse Dynamics GmbH’s regional and country manager. In that role, according to the press release, he was “responsible for sales and marketing activities, launching a new therapy for symptomatic heart failure, distributor management as well as customer training and education.”
Before joining Impulse Dynamics, Ojala worked in sales and marketing roles for Medtronic, focusing on its medical device portfolio. He also worked as a sales representative for Oriola-KD Healthcare.
Bioretec Chief Executive Officer Timo Lehtonen commented, “We are delighted to have Rami Ojala strengthen Bioretec’s Management Team and lead the company’s sales and marketing operations. Bioretec’s vision is to become a globally recognized medical device company and a leader in bioresorbable metal implants.”
Lehtonen continued, “Rami [Ojala] will play a significant role in executing our growth strategy through driving sales and finding new growth avenues. His comprehensive competence and international experience from medical devices, launching new products and therapies, opening new geographical markets and working with distributors will meet our needs perfectly and support our growth journey. I would also like to warmly thank Lauri Hokkanen for his contribution in Bioretec’s sales and marketing activities and wish him all the best for the future.”
Bioretec develops bioresorbable orthopedic implants for both adults and pediatrics. Its new RemeOs™ implant product line is in the clinical testing phase. Per its website, RemeOs “implants will offer a strong and bioresorbable solution for load-bearing medical operations indications.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.